The Hepatoprotective Effects of Ginsenoside from Ginseng : A Review of Molecular Mechanisms and Therapeutic Potentials
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Treatment of hepatic diseases presents a significant challenge due to their diverse nature. Ginsenosides, bioactive compounds derived from the root of Panax ginseng and widely used in traditional Chinese medicine, offer multifaceted protection to various organs in the body. Their versatile effects, including antioxidant, anti-inflammatory, anti-apoptotic and more, make them a promising approach for addressing hepatic disorders. This review explores the intricate molecular mechanisms and properties of ginsenosides in the prevention and treatment of liver ailments, from mild conditions to severe damage and liver fibrosis. Given the increasing prevalence of hepatic disorders, this article sheds light on the significant pharmaceutical potential of ginsenosides in the realm of hepatic disease management.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Current pharmaceutical biotechnology - (2024) vom: 28. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Taha, Seyed Reza [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alcoholic liver disease |
|---|
| Anmerkungen: |
Date Revised 29.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0113892010291326240214095327 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369143108 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369143108 | ||
| 003 | DE-627 | ||
| 005 | 20240301233304.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0113892010291326240214095327 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1313.xml |
| 035 | |a (DE-627)NLM369143108 | ||
| 035 | |a (NLM)38424417 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Taha, Seyed Reza |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Hepatoprotective Effects of Ginsenoside from Ginseng |b A Review of Molecular Mechanisms and Therapeutic Potentials |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Treatment of hepatic diseases presents a significant challenge due to their diverse nature. Ginsenosides, bioactive compounds derived from the root of Panax ginseng and widely used in traditional Chinese medicine, offer multifaceted protection to various organs in the body. Their versatile effects, including antioxidant, anti-inflammatory, anti-apoptotic and more, make them a promising approach for addressing hepatic disorders. This review explores the intricate molecular mechanisms and properties of ginsenosides in the prevention and treatment of liver ailments, from mild conditions to severe damage and liver fibrosis. Given the increasing prevalence of hepatic disorders, this article sheds light on the significant pharmaceutical potential of ginsenosides in the realm of hepatic disease management | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Ginsenoside | |
| 650 | 4 | |a alcoholic liver disease | |
| 650 | 4 | |a drug-induced liver injury | |
| 650 | 4 | |a hepatic ischemia-reperfusion injury | |
| 650 | 4 | |a liver fibrosis. | |
| 650 | 4 | |a non-alcoholic fatty liver disease | |
| 650 | 4 | |a viral hepatitis | |
| 700 | 1 | |a Fazlollahpour-Naghibi, Andarz |e verfasserin |4 aut | |
| 700 | 1 | |a Zadeh, Mahdieh Shariat |e verfasserin |4 aut | |
| 700 | 1 | |a Bagheri, Kimia |e verfasserin |4 aut | |
| 700 | 1 | |a Youshanlouei, Hamed Rahmani |e verfasserin |4 aut | |
| 700 | 1 | |a Mosaddeghi-Heris, Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Hejazian, Seyyed Sina |e verfasserin |4 aut | |
| 700 | 1 | |a Khalaji, Amirreza |e verfasserin |4 aut | |
| 700 | 1 | |a Alavi, Seyedeh Shaghayegh |e verfasserin |4 aut | |
| 700 | 1 | |a Fattahi, Payam |e verfasserin |4 aut | |
| 700 | 1 | |a Mehrtabar, Saba |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical biotechnology |d 2000 |g (2024) vom: 28. Feb. |w (DE-627)NLM11369072X |x 1873-4316 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:28 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0113892010291326240214095327 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 28 |c 02 | ||